Second PSMA PET Scans Significantly Influence Prostate Cancer Management

A recent study published in the July issue of The Journal of Nuclear Medicine has revealed that repeating PSMA PET scans can lead to changes in the treatment strategy for almost half of the prostate cancer patients who initially show negative results. This finding is crucial for managing recurrent prostate cancer, particularly following first-line treatments such as prostatectomy or radiation therapy.

Prostate cancer recurrence is often indicated by elevated prostate-specific antigen (PSA) levels, even when initial PSMA PET scans fail to detect the disease in approximately 30% of cases. The study, led by Dr Ur Metser from the University of Toronto, sought to explore the usefulness of a second PSMA PET scan in such scenarios and identify factors that predict positive scan outcomes.

The research involved 210 patients from Ontario's Registry for Recurrent Prostate Cancer. These patients had undergone more than one PSMA PET scan following an initial negative result. The team compared the scan positivity rates, levels of serum PSA, PSA doubling time, and management changes observed after the second scan.

Results showed that 56% of the patients with an initially negative PSMA PET scan had detectable disease when re-evaluated with a second scan. Consequently, the management plans were altered for nearly 50% of them, particularly those with oligometastatic disease, which indicates fewer than five positive disease sites. The likelihood of disease detection was higher in patients with elevated PSA levels and a PSA doubling time of less than 12 months.

Dr Metser and his colleagues stress the importance of PSMA PET scans in managing prostate cancer recurrences. “Understanding the extent of the disease in patients who have initial negative PSMA PET scans provides valuable information for physicians as they create treatment plans,” he noted.

The study’s authors include contributing researchers from institutions such as the University of Toronto, Western University, and Ontario Health (Cancer Care Ontario). They underscore the pivotal role that repeated PSMA PET imaging could play in refining treatment decisions and improving outcomes for patients facing recurrent prostate cancer.